GO-Pen ApS is a start-up company established in 2019 by Ole Kjerkegaard Nielsen and Michael Ejstrup Hansen.
Our ambition is to develop safe, affordable medical devices that can help the many people for whom modern medical products today are unattainable.
The flag-ship product is the first price neutral and climate friendly insulin pen for the resource poor.
GO-Pen is a DK-based medical device company that delivers affordable, safe medical devices to people with few resources.
We have deep experience with the global, unmet needs for patients with diabetes and medical device development provides.
Our team has unique competencies to develop a product that can be mass produced with unique differentiation and market appeal.
We hope to make insulin injection easier and better and thereby addressing unmet health needs in the world’s most resource constrained populations.
Ole is partner and founder of GO-Pen Aps.
With 9 years as head of department at Novo Nordisk, Ole has deep insight into the unmet needs of the most disadvantaged people with diabetes in developing countries.
As head of Coloplast A/S's clinical development department, Ole focused on the development of medical devices in relation to current and future regulatory requirements in the EU and the US, made medical due diligence in connection with external product purchases, and adapted the development programs to take into account international marketing requirements
Michael is partner and founder of GO-Pen Aps.
Michael has a solid background in medical device development, has co-authored 29 patents through his 18 years as an external developer for the Novo Nordisk device department.
Over the years as a developer for Novo Nordisk, Michael has had roles as project manager for a specialist in mechanical development of medical devices.
Michael has a unique insight into, preparation of IPR documentation, mechanical design / analysis, prototype and design of injection molding tools, design stability analysis of tools, development of quality assurance systems, plastic biocompatibility protocols and planning and implementation of production maturation